BOLD

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Boundless Bio Inc revenue for the last quarter amounts to -15.15M USD, decreased -19.06 % YoY.

Boundless Bio Inc. EPS for the last quarter amounts to -10210000.00 USD, decreased -25.74 % YoY.

Boundless Bio Inc (BOLD) has 64 emplpoyees as of December 16 2025.

Today BOLD has the market capitalization of 25.52M USD.